Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Price:
93.33
CNY
1.89%
Market Closed
Market Cap:
¥24.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
|
CN |
|
N
|
NBTM New Materials Group Co Ltd
SSE:600114
|
CN |
|
Advanced Technology & Materials Co Ltd
SZSE:000969
|
CN |
|
A
|
Answear.Com SA
WSE:ANR
|
PL |
|
N
|
Ningbo Shanshan Co Ltd
SSE:600884
|
CN |
|
I
|
Iljin Power Co Ltd
KOSDAQ:094820
|
KR |
|
Sado Steam Ship Co Ltd
TSE:9176
|
JP |
|
China Youzan Ltd
HKEX:8083
|
HK |
|
Eukedos SpA
MIL:EUK
|
IT |
|
P
|
PT Era Digital Media Tbk
IDX:AWAN
|
ID |
Multiples-Based Value
The Multiples-Based Value of one
Suzhou Zelgen Biopharmaceuticals Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 93.33 CNY,
Suzhou Zelgen Biopharmaceuticals Co Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Suzhou Zelgen Biopharmaceuticals Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
|
24.7B CNY | 41.8 | -195.4 | -146.2 | -146.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 6.1 | 88.4 | 14.7 | 20.4 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.4B USD | 109.4 | -1 708.3 | 15 870 | -1 791.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 5.7 | 19.6 | 12.3 | 15.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.2 | 27.8 | 20.9 | 21.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.2 | 35.1 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
